|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 97.10 USD | -0.60% |
|
+1.26% | -1.69% |
| 14/04 | Pharma sector doubles down on AI amid hopes of slashing costs, timelines | RE |
| 08/04 | Palvella Therapeutics, Inc. Appoints Kent Taylor as Senior Vice President of Sales | CI |
| Fiscal Period: December | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
Revenues | 298.63Cr | 339.46Cr | 369.56Cr | 424.12Cr | 514.12Cr | |||||
Other Revenues, Total | - | - | - | - | - | |||||
Total Revenues | 298.63Cr | 339.46Cr | 369.56Cr | 424.12Cr | 514.12Cr | |||||
Cost of Goods Sold, Total | 164.62Cr | 180.09Cr | 188.46Cr | 290.66Cr | 242.23Cr | |||||
Gross Profit | 134.01Cr | 159.37Cr | 181.1Cr | 133.46Cr | 271.9Cr | |||||
Selling General & Admin Expenses, Total | 74Cr | 100Cr | 115.87Cr | 121.87Cr | 137.25Cr | |||||
Other Operating Expenses, Total | 74Cr | 100Cr | 115.87Cr | 121.87Cr | 137.25Cr | |||||
Operating Income | 60Cr | 59Cr | 65Cr | 12Cr | 134.65Cr | |||||
Interest Expense, Total | -19.08L | -26.66L | -25.51L | -22.8L | -24.28L | |||||
Interest And Investment Income | - | - | 17Cr | 13Cr | 11Cr | |||||
Net Interest Expenses | -19.08L | -26.66L | 17Cr | 13Cr | 10Cr | |||||
Other Non Operating Income (Expenses) | 1.2Cr | 3.71Cr | - | 95.29L | 2.14Cr | |||||
EBT, Excl. Unusual Items | 61Cr | 63Cr | 82Cr | 25Cr | 147.1Cr | |||||
Merger & Related Restructuring Charges | - | - | - | -3.15Cr | - | |||||
Gain (Loss) On Sale Of Investments | -2.41Cr | -8.76Cr | 4.39Cr | 12Cr | 2.13Cr | |||||
Asset Writedown | - | - | - | - | -7.63Cr | |||||
Legal Settlements | - | - | - | - | 24Cr | |||||
Other Unusual Items | -1.47Cr | -1.21Cr | -2.92Cr | -1.98Cr | 61.29L | |||||
EBT, Incl. Unusual Items | 57Cr | 53Cr | 83Cr | 32Cr | 166.45Cr | |||||
Income Tax Expense | -38Cr | 19Cr | 24Cr | 28Cr | 38Cr | |||||
Earnings From Continuing Operations | 95Cr | 34Cr | 60Cr | 3.26Cr | 128.66Cr | |||||
Net Income to Company | 95Cr | 34Cr | 60Cr | 3.26Cr | 128.66Cr | |||||
Net Income - (IS) | 95Cr | 34Cr | 60Cr | 3.26Cr | 128.66Cr | |||||
Net Income to Common Incl Extra Items | 95Cr | 34Cr | 60Cr | 3.26Cr | 128.66Cr | |||||
Net Income to Common Excl. Extra Items | 95Cr | 34Cr | 60Cr | 3.26Cr | 128.66Cr | |||||
Per Share Items | ||||||||||
Net EPS - Basic | 4.3 | 1.53 | 2.67 | 0.16 | 6.59 | |||||
Basic EPS - Continuing Operations | 4.3 | 1.53 | 2.67 | 0.16 | 6.59 | |||||
Basic Weighted Average Shares Outstanding | 22Cr | 22Cr | 22Cr | 21Cr | 20Cr | |||||
Net EPS - Diluted | 4.27 | 1.52 | 2.65 | 0.15 | 6.41 | |||||
Diluted EPS - Continuing Operations | 4.27 | 1.52 | 2.65 | 0.15 | 6.41 | |||||
Diluted Weighted Average Shares Outstanding | 22Cr | 22Cr | 23Cr | 21Cr | 20Cr | |||||
Normalized Basic EPS | 1.73 | 1.77 | 2.29 | 0.76 | 4.71 | |||||
Normalized Diluted EPS | 1.71 | 1.75 | 2.27 | 0.75 | 4.58 | |||||
American Depositary Receipts Ratio (ADR) | 0.5 | 0.5 | 0.5 | 0.5 | 0.5 | |||||
Supplemental Items | ||||||||||
EBITDA | 66Cr | 67Cr | 74Cr | 21Cr | 143.98Cr | |||||
EBITA | 62Cr | 62Cr | 67Cr | 14Cr | 137.32Cr | |||||
EBIT | 60Cr | 59Cr | 65Cr | 12Cr | 134.65Cr | |||||
EBITDAR | 67Cr | 68Cr | 75Cr | 22Cr | 144.75Cr | |||||
Total Revenues (As Reported) | 298.63Cr | 339.46Cr | 369.56Cr | 424.12Cr | 514.12Cr | |||||
Effective Tax Rate - (Ratio) | -66.29 | 35.62 | 28.36 | 89.7 | 22.7 | |||||
Current Domestic Taxes | 8.31Cr | 13Cr | 39Cr | 37Cr | 12Cr | |||||
Current Foreign Taxes | 43.97L | 31.41L | 30.01L | 29.31L | 66.1L | |||||
Total Current Taxes | 8.75Cr | 13Cr | 40Cr | 37Cr | 13Cr | |||||
Deferred Domestic Taxes | -41Cr | 5.84Cr | -16Cr | -8.47Cr | 25Cr | |||||
Deferred Foreign Taxes | -75T | -13.07L | 2L | -8L | 3L | |||||
Total Deferred Taxes | -41Cr | 5.71Cr | -16Cr | -8.56Cr | 25Cr | |||||
Normalized Net Income | 38Cr | 39Cr | 51Cr | 16Cr | 92Cr | |||||
Interest on Long-Term Debt | 13L | 14L | 13L | 13L | 13L | |||||
Non-Cash Pension Expense | 14.03L | -28.04L | -26.37L | -32.8L | -37.3L | |||||
Supplemental Operating Expense Items | ||||||||||
Advertising Expense | 6.6Cr | 20Cr | 22Cr | 20Cr | 16Cr | |||||
Selling and Marketing Expenses | 6.6Cr | 20Cr | 22Cr | 20Cr | 16Cr | |||||
Research And Development Expense From Footnotes | 148.78Cr | 163.81Cr | 167.67Cr | 263.67Cr | 206.62Cr | |||||
Net Rental Expense, Total | 1.5Cr | 1.17Cr | 98L | 81L | 77L | |||||
Imputed Operating Lease Interest Expense | 37.49L | 43.03L | 36.99L | 26.17L | 25.95L | |||||
Imputed Operating Lease Depreciation | 1.13Cr | 73.97L | 61.01L | 54.83L | 51.05L | |||||
Stock-Based Comp., COGS (Total) | 12Cr | 12Cr | 13Cr | 16Cr | 15Cr | |||||
Stock-Based Comp., SG&A Exp. (Total) | 6.7Cr | 7.32Cr | 8.61Cr | 10Cr | 9.56Cr | |||||
Stock-Based Comp., Other (Total) | - | - | - | - | 46T | |||||
Total Stock-Based Compensation | 18Cr | 19Cr | 22Cr | 27Cr | 25Cr |
- Stock Market
- Equities
- INCY Stock
- Financials Incyte Corporation
- Income Statement
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition















